Evofem Biosciences Inc (PK:EVFM)

Business Focus: Pharmaceuticals

Mar 27, 2024 08:36 am ET
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
-- Third Consecutive Year of Phexxi Net Sales Growth --
Feb 01, 2024 07:00 am ET
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
Evofem Delivers Third Consecutive Year of Phexxi Net Sales Growth 
Jan 08, 2024 07:30 am ET
Washington State HCA Removes Prior Authorization for Hormone-Free "In the Moment" Contraceptive PHEXXI Ahead of Huskies vs. Wolverines Championship Game
— Removal of Prior Authorization Upgrades Phexxi Coverage for Nearly 1.8 Million Washington Lives Across All Medicaid Plans —
Dec 19, 2023 10:38 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, EVFM, AEZS, HOLI
NEW YORK, Dec. 19, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Dec 18, 2023 03:19 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AYX, EVFM, CNSL
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Alteryx, Inc. (NYSE: AYX)’s sale to...
Dec 18, 2023 02:30 pm ET
EVOFEM BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Evofem Biosciences, Inc. - EVFM
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Evofem Biosciences, Inc. (OTC: EVFM) to Aditxt, Inc. (NasdaqCM: ADTX) in consideration of the issuance of a combination of common stock and preferred stock, and the assumption of certain senior indebtedness, having an aggregate amount of approximately $100 million. KSF is seeking to determine whether the merger and the process that led to it are adequate and fair to the Company’s shareholders.
Dec 18, 2023 12:57 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Eagle Bulk Shipping Inc. (NYSE - EGLE), Icosavax, Inc. (Nasdaq - ICVX), Evofem Biosciences, Inc. (OTC - EVFM),
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Dec 14, 2023 01:23 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVLY, ADTX, EVFM
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Codorus Valley Bancorp, Inc. (NASDAQ:...
Dec 13, 2023 08:00 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger – EAR, IMGN, CVLY, EVFM
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and headquartered...
Dec 13, 2023 11:48 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CSTR, CVLY, EVFM, EAR
NEW YORK, Dec. 13, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Dec 12, 2023 01:44 pm ET
Shareholder Alert: Ademi LLP investigates whether Evofem Biosciences, Inc. has obtained a Fair Price in its transaction with Aditxt
MILWAUKEE, Dec. 12, 2023 /PRNewswire/ -- Ademi LLP is investigating Evofem (OTCQB: EVFM) for possible breaches of fiduciary duty and other violations of law in its transaction with Aditxt.
Dec 12, 2023 11:47 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Eagle Bulk Shipping Inc. (NYSE - EGLE), Icosavax, Inc. (Nasdaq - ICVX), Evofem Biosciences, Inc. (OTC - EVFM),
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Dec 12, 2023 09:54 am ET
EVFM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Evofem Biosciences, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Evofem Biosciences, Inc. (OTCQB: EVFM) and Aditxt, Inc. is fair to Evofem shareholders.
Dec 12, 2023 08:30 am ET
Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive H
Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, and Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM), a pioneer in women’s health, today announced the signing of a definitive agreement (the “Agreement”) under which Aditxt is to acquire Evofem in consideration of the issuance of a combination of common stock and preferred stock, and the assumption of certain senior indebtedness, having an aggregate amount of approximately $100 million (the “Transaction”). Pending a successful Transaction, it wi
Nov 14, 2023 05:56 am ET
Evofem Biosciences Announces Financial Results for the Third Quarter of 2023
— On track to achieve third consecutive year of revenue growth –
Oct 24, 2023 07:36 am ET
Evofem Biosciences Announces Preliminary Results for the Third Quarter of 2023
— On track to achieve third consecutive year of net product sales growth —
Oct 13, 2023 11:36 am ET
Evofem to Participate in the Virtual Investor Ask the CEO Conference
-- Live moderated video webcast with members of Evofem management team on Tuesday, October 24th at 10:00 AM ET --
Sep 27, 2023 08:47 am ET
Sep 11, 2023 08:00 am ET
Evofem Biosciences Successfully Amends S.P.A. with Institutional Investor
-- Investor withdraws March 2023 Notice of Default --
Jul 06, 2023 08:42 am ET
Evofem to Participate in the Virtual Investor Summer Spotlight Series
-- Live moderated video webcast with members of Evofem management team on Wednesday, July 12th at 4:00 p.m. ET --
Jun 01, 2023 08:36 am ET
Evofem Biosciences Announces Strong Preliminary Results for the First Quarter of 2023
Increased net product revenue more than 35% in the first quarter of 2023 vs. prior year quarter
May 17, 2023 04:50 pm ET
Evofem Biosciences Announces 1-for-125 Reverse Stock Split
-- CUSIP number for Evofem will change to 30048L302 on May 18, 2023 --
Apr 28, 2023 06:50 am ET
Evofem Biosciences Reports Year-End 2022 Financial Results and Provides Corporate Update
-- Net product sales more than doubled in 2022 vs. prior year --
Apr 14, 2023 09:00 am ET
Evofem Appoints Ivy Zhang as Chief Financial Officer and Secretary
SAN DIEGO, April 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), today announced the appointment of Ivy Zhang as Chief Financial Officer (CFO) and Secretary, effective April 13, 2023. Reporting to Chief Executive Officer Saundra Pelletier, Ms. Zhang will lead Evofem's finance organization and financial activities including financial planning and analysis, accounting, external audit, tax, controllership, and treasury functions.
Apr 12, 2023 08:48 am ET
Evofem Wins Phexxi Coverage with Largest Payer in New York with No Prior Authorization Required
— Improves Phexxi coverage for more than 5.8 million New York lives —
Mar 21, 2023 08:48 am ET
Evofem Biosciences Announces Cost Reduction Measures
– Company cuts management pay and lowers headcount to decrease operating costs –
Mar 09, 2023 05:50 am ET
Evofem Biosciences Appoints Interim Chief Financial Officer
SAN DIEGO, March 9, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) is pleased to announce the appointment of Albert Altro as Interim Chief Financial Officer of the Company. He replaces Jay File, who is leaving the Company to explore other opportunities.
Feb 27, 2023 06:46 am ET
Evofem Biosciences Announces FDA Orange Book Listing of Two Additional U.S. Patents for Phexxi
-- Evofem now has four Orange Book listed patents covering Phexxi into 2033 -- 
Jan 12, 2023 07:36 am ET
Evofem's Phexxi Contraceptive Gel to be Offered by Female Telehealth Leader Favor (Formerly The Pill Club)
-- Phexxi is the first and only hormone-free contraceptive in the Favor product portfolio --
Jan 10, 2023 07:36 am ET
Costco Adds Phexxi® to Member Prescription Program
SAN DIEGO, Jan. 10, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that Phexxi® (lactic acid, citric acid, potassium bitartrate) has been added to the Costco Member Prescription Program, giving millions of additional women access to this innovative hormone-free contraceptive.
Jan 09, 2023 07:54 am ET
Multiple New Insurance Wins Expand and Improve Access to Phexxi® for Millions of Women
-- Medicaid improves Phexxi coverage for more than 3.7 million lives across 11 states --
Dec 29, 2022 03:48 pm ET
OTC Markets Group Grants Evofem Additional Time to File Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2022
SAN DIEGO, Dec. 29, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced that it has been granted additional time by the OTC Markets Group to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (the "10-Q").  Previously, the OTC Markets Group provided until December 29, 2022 to file the 10-Q . The extended deadline is now January 6, 2023.
Oct 11, 2022 09:00 pm ET
Evofem Reports Top-Line Results from Phase 3 EVOGUARD Clinical Trial Evaluating EVO100 for Prevention of Chlamydia and Gonorrhea Infection in Women
SAN DIEGO, Oct. 11, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) announced today that the recently completed Phase 3 EVOGUARD clinical trial evaluating EVO100 for the prevention of chlamydia and gonorrhea infection in women did not achieve its endpoints.
Oct 06, 2022 08:46 am ET
Evofem Biosciences Announces Approval of Phexxi in Nigeria
-- First Regulatory Approval Outside the U.S. --
Oct 03, 2022 08:30 am ET
Evofem Biosciences Announces Uplisting to OTCQB
SAN DIEGO, Oct. 3, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB: EVFM) announced today that the trading of its common shares has been upgraded to the OTCQB Venture Market from the OTC Pink Open Market. The Company's ticker symbol remains the same.
Sep 23, 2022 09:00 am ET
Evofem Announces Issuance of U.S. Patent Covering Phexxi® Composition of Matter
-- Issuance of U.S. Patent No. 11,439,610 Further Strengthens Evofem's Intellectual Patent Portfolio --
Sep 19, 2022 09:00 am ET
Inventor of the Year Awarded to Developer of Phexxi®
-- Dr. Donald Waller Honored by University of Illinois Chicago --
Sep 16, 2022 09:00 am ET
Large Commercial Payer Adds Phexxi® to Formulary for Standard Plans Nationwide
-- One of the Largest Commercial Payers in the U.S. Expands Access to Phexxi® for Women Seeking FDA-Approved, Hormone-Free Contraception --
Sep 16, 2022 06:00 am ET
Evofem Announces Successful Debt Restructuring
-- Evofem Gains Forbearance from Debtholders for All Existing Matters--
Aug 10, 2022 08:23 pm ET
Evofem Biosciences to Host Investor Call on Thursday, August 11, 2022
-- Conference Call Scheduled for 5:00 p.m. ET --
Aug 10, 2022 10:40 am ET
Thinking about buying stock in Ford, Evofem Biosciences, Roblox, AMC Entertainment, or SilverSun Technologies?
NEW YORK, Aug. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for F, EVFM, RBLX, AMC, and SSNT.
Aug 05, 2022 08:32 am ET
Thinking about buying stock in Evofem Biosciences, Plug Power, FuboTV, Staffing 360 Solutions, or ACM Research?
NEW YORK, Aug. 5, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EVFM, PLUG, FUBO, STAF, and ACMR.
Aug 04, 2022 04:01 pm ET
Evofem Biosciences Announces Strong Second Quarter 2022 Financial Results and Affirms 2022 Guidance
-- 42% growth in Phexxi® (lactic acid, citric acid and potassium bitartrate) net product sales quarter over quarter --
Aug 03, 2022 08:24 am ET
Evofem Biosciences Strengthens Board of Directors
SAN DIEGO, Aug. 3, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced the appointment of Jenny Yip, a Managing Partner at life sciences investment fund Adjuvant Capital, to its Board of Directors. The appointment of Ms. Yip as a director expands the Board from five to six independent directors.
Aug 01, 2022 09:00 am ET
Evofem Biosciences Discusses Innovative Woman-Controlled Contraceptive with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - August 1, 2022) - The Stock Day Podcast welcomed Evofem Biosciences (NASDAQ: EVFM) ("the Company"), an innovator in women's sexual and reproductive health and the maker of hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate). Evofem's CEO, Saundra Pelletier, joined Stock Day host Sever Copley.
Jul 29, 2022 08:32 am ET
Thinking about buying stock in Toughbuilt Industries, Exela Technologies, Bausch Health, Fluence Energy, or Evofem Biosciences?
NEW YORK, July 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TBLT, XELA, BHC, FLNC, and EVFM.
Jul 29, 2022 08:24 am ET
Evofem Biosciences Commends Tri-Agencies for Clarifying that Contraceptives Must be Covered at No Cost to Individuals
SAN DIEGO, July 29, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM), a women's healthcare company, today commended the U.S. Department of Health and Human Services, alongside the Departments of Labor and of the Treasury ("the Tri-Agencies"), for taking action to clarify protections for birth control coverage under the Affordable Care Act (ACA).
Jul 28, 2022 08:47 am ET
Jul 26, 2022 08:47 am ET
Evofem's House Rules Campaign Featuring Annie Murphy Receives Significant Industry Recognition
Evocative direct-to-consumer (DTC) campaign has received 12 healthcare and communications industry awards to date and has recently been shortlisted for four more awards. The national campaign features Emmy® Award-winning spokeswoman and actress Annie Murphy and was created to generate awareness of Evofem's hormone-free contraceptive, Phexxi, while also highlighting the contraceptive journey of millions of women, like Annie, who are tired of dealing with the side effects of hormones in their birth control.To date, the House Rules campaign has grown brand awareness by 45%, garnered 42 million
Jul 25, 2022 08:47 am ET
Evofem Biosciences Unveils New Educational Birth Control Chart to Assist Providers in Patient Contraceptive Counseling
SAN DIEGO, July 25, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced it has developed a new educational birth control chart that provides high-level information about the different options available to women in the United States.
Jul 22, 2022 08:47 am ET
Evofem Biosciences Applauds U.S. House of Representatives for Passing The Right to Contraception Act
SAN DIEGO, July 22, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM), a women's healthcare company, today applauded the 228 members of the U.S. House of Representatives who voted to pass legislation to safeguard access to contraceptives entitled The Right to Contraception Act.
Jul 21, 2022 08:46 am ET
Evofem Partners with a360 Media to Support Phexxi® Prescription Growth
Agreement with a360 Media Delivers Phexxi Branded Content in Leading Entertainment and Lifestyle Magazines
Jul 18, 2022 10:59 am ET
Thinking about buying stock in Carnival Corp, New Oriental Education, Evofem Biosciences, Li Auto, or Vertical Aerospace?
NEW YORK, July 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CCL, EDU, EVFM, LI, and EVTL.
Jul 12, 2022 09:35 am ET
Thinking about buying stock in Inmode, Evofem Biosciences, Scholar Rock, Verrica Pharmaceuticals, or Indonesia Energy?
NEW YORK, July 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INMD, EVFM, SRRK, VRCA, and INDO.
Jul 12, 2022 08:46 am ET
Phexxi® Mechanism of Action Article Published in the Journal of Therapeutic Advances in Reproductive Health
SAN DIEGO, July 12, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) announced today that the Journal of Therapeutic Advances in Reproductive Health has published Mechanisms of action of currently available woman-controlled, vaginally administered, non-hormonal contraceptive products, a peer-reviewed article defining and reconfirming the mechanism of action (MOA) of Phexxi® (lactic acid, citric acid, potassium bitartrate).
Jun 30, 2022 08:46 am ET
Evofem Strengthens Phexxi® Intellectual Property with New Composition of Matter Patent From USPTO
SAN DIEGO, June 30, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) announced today that the United States Patent and Trademark Office (USPTO) issued to the Company a Notice of Allowance for patent application 16/738,868 entitled, "Compositions and Methods for Enhancing the Efficacy of Contraceptive Microbicides" which covers the composition of matter of Phexxi® (lactic acid, citric acid, potassium bitartrate) and is expected to provide protection into at least 2033. 
Jun 29, 2022 09:31 am ET
Thinking about buying stock in Biotricity, Ford Motor, Evofem Biosciences, Nokia, or Rivian Automotive?
NEW YORK, June 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BTCY, F, EVFM, NOK, and RIVN.
Jun 28, 2022 08:30 am ET
Thinking about buying stock in Kezar Life Sciences, Evofem Biosciences, Agile Therapeutics, Sutro Biopharma, or Wejo Group?
NEW YORK, June 28, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KZR, EVFM, AGRX, STRO, and WEJO.
Jun 28, 2022 06:48 am ET
Evofem Reaches Agreement with One of the Largest Pharmacy Benefit Managers in the U.S. for Access to Phexxi®
Agreement Significantly Expands Access to Phexxi® for Millions of Women Seeking an FDA-Approved, Hormone-Free, On-Demand Option to Prevent PregnancyLong-term Contract Adds to Growing List of Agreements with Payers Opening New and Significant Access to PhexxiEvofem Expects Increases in Phexxi Prescriptions and Significant Cost-Savings from AgreementsSAN DIEGO, June 28, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced it has reached an agreement with one of the nation's largest pharmacy benefit managers (PBMs) to ensure most women covered by this plan can fill thei
Jun 27, 2022 08:30 am ET
Thinking about buying stock in Epizyme, Acutus Medical, Agile Therapeutics, Axsome Therapeutics, or Evofem Biosciences?
NEW YORK, June 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EPZM, AFIB, AGRX, AXSM, and EVFM.
Jun 16, 2022 08:46 am ET
Phexxi® Prevented 99% of Pregnancies Per Act of Intercourse in a Post Hoc Analysis of Phase 3 AMPOWER Clinical Trial Data
Throughout 24,289 Acts of Intercourse, 101 Pregnancies were Reported with Typical Use of Phexxi in AMPOWER Post Hoc AnalysisSAN DIEGO, June 16, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced results of a post hoc analysis of the registrational Phase 3 AMPOWER trial investigating the ability of Phexxi® (lactic acid, citric acid, and potassium bitartrate) to prevent pregnancy.
Jun 02, 2022 08:46 am ET
US Food and Drug Administration Extends Phexxi® Shelf Life to Four Years
SAN DIEGO, June 2, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced that the U.S. Food and Drug Administration (FDA) has formally extended the shelf life of Phexxi® (lactic acid, citric acid, potassium bitartrate) from three to four years.
May 20, 2022 09:13 am ET
Evofem Biosciences Announces Pricing of Approximately $26.6 Million Public Offering
SAN DIEGO, May 20, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced the pricing of its previously announced underwritten public offering of 22,665,000 shares of its common stock, 12,835,000 pre-funded warrants to purchase common stock in lieu of common stock to certain investors and warrants to purchase up to 71,000,000 shares of its common stock. Each share of common stock and accompanying common warrant are being offered at a combined public offering price of $0.75, less underwriting discounts and commissions, and each pre-funded warrant and accompanyin
May 19, 2022 05:59 pm ET
Evofem Biosciences Announces Proposed Public Offering
SAN DIEGO, May 19, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (Nasdaq: EVFM) (Evofem) today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase common stock in lieu of common stock to certain investors) and warrants to purchase shares of its common stock in an underwritten public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares of common stock, pre-funded warr
May 10, 2022 08:46 am ET
Evofem Biosciences to Decrease Cost of Goods 45 Percent Through New Partnership with Bora Pharmaceutical Services for the Commercial Manufacturing of Phexxi®
SAN DIEGO, May 10, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced it has selected Bora Pharmaceuticals Services Inc. (Bora) Canada as Evofem's new contract manufacturing organization (CMO). Bora will eventually manufacture Phexxi® (lactic acid, citric acid, and potassium bitartrate) for markets worldwide.
May 06, 2022 08:46 am ET
Evofem Presents Data Detailing Fewer Urinary Tract Infections in Women Using Phexxi in the Phase 3 AMPOWER Clinical Trial
5.8% of Women in the AMPOWER Trial Experienced an On-Study Urinary Tract Infection Compared to 11% in the General PopulationThe Post hoc Analysis will be Presented at the 2022 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting in San Diego, CA on May 7, 2022SAN DIEGO, May 6, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced that new data from the Phase 3 AMPOWER clinical trial of Phexxi® (lactic acid, citric acid, and potassium bitartrate) showed that women enrolled in the AMPOWER trial had fewer urinary tract infections (UTIs) compared to t
May 05, 2022 10:45 am ET
Thinking about buying stock in Nikola Corp, Marathon Oil, eBay, Redbox Entertainment, or Evofem Biosciences?
NEW YORK, May 5, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NKLA, MRO, EBAY, RDBX, and EVFM.
May 05, 2022 09:00 am ET
Evofem Biosciences Announces 1-for-15 Reverse Stock Split
SAN DIEGO, May 5, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) (the "Company") today announced that the Board and stockholders of the Company approved a 1-for-15 reverse stock split of the Company's common stock at the annual meeting of the Company held on May 4, 2022. The reverse stock split will take effect at the close of trading on the Nasdaq Capital Market, or 4:00 p.m. Eastern Time, on Thursday, May 5, 2022. The Company's common stock will open for trading under a new CUSIP on the Nasdaq Capital Market on May 6, 2022, on a split-adjusted basis under the current ticker
May 04, 2022 04:01 pm ET
Apr 27, 2022 08:46 am ET
Evofem Improves Phexxi® Patient Experiences Through New Agreement with VitaCare Prescription Services
Evofem Anticipates Greater Numbers of Phexxi® (lactic acid, citric acid, potassium bitartrate) Prescriptions Filled as a Result of VitaCare AgreementNew Agreement Provides More Efficient Patient Follow-Up Practices for Women Prescribed Phexxi through VitaCare Prescription Services with Enhanced "White Glove" Support ServicesSAN DIEGO, April 27, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) announced today that it has entered into a new agreement with VitaCare Prescription Services, a wholly-owned subsidiary of GoodRx, to provide enhanced "white glove" support services to wome
Apr 26, 2022 08:46 am ET
Evofem to Present New Research in Gynecological Health at the 2022 American College of Obstetricians and Gynecologists Annual Meeting
SAN DIEGO, April 26, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced it will present new data from the Phase 3 AMPOWER Clinical Trial at the 2022 American College of Obstetricians and Gynecologists (ACOG) annual meeting. The poster presentation details the characterization of women who experienced urinary tract infections (UTIs) during the AMPOWER Study.
Apr 25, 2022 09:00 am ET
Apr 19, 2022 06:52 am ET
Journal of Sexual Medicine Publishes Sexual Satisfaction Data Involving Phexxi® from Evofem's Phase 3 AMPOWER Clinical Trial
88.7% of Women Using Phexxi® (lactic acid, citric acid, and potassium bitartrate Vaginal Gel) Improved or Maintained their Sex Life According to Exploratory Data Collected During the Phase 3 AMPOWER Clinical Trial Women in the Study Provided Data Measured by 10 Variables Ranging from the Ability to Climax to Interest in Having Sex Phexxi is FDA Approved to Prevent PregnancySAN DIEGO, April 19, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced the Journal of Sexual Medicine, a peer-reviewed medical journal, published data collected from Evofem's Phase 3 AMPOWER cl
Apr 11, 2022 06:48 am ET
Evofem Announces Karina Fedasz as Company's New Head of Business Development
Fedasz will Focus on Opening New Markets for Evofem's First - and Only – in-Class Contraceptive, Phexxi® (lactic acid, citric acid, and potassium bitartrate)SAN DIEGO, April 11, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced the appointment of Karina Fedasz as its Head of Business Development. At Evofem, Karina will oversee the company's business development, product and pipeline portfolios, new business ventures, and the advancement of access partnerships around the world.
Apr 07, 2022 10:55 am ET
Thinking about buying stock in SoFi Technologies, Tilray, Evofem Biosciences, Uranium Energy, or Missfresh?
NEW YORK , April 7, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SOFI, TLRY, EVFM, UEC, and MF.
Apr 07, 2022 06:50 am ET
Nasdaq Accepts Evofem Plan to Regain Listing Compliance
Continued Listing Subject to Receipt of Shareholder Approval for the Reverse Stock Split of Evofem Common Stock before May 4, 2022, with Compliance by May 20, 2022
Mar 31, 2022 01:00 pm ET
Evofem Presents Positive Encore Data in Sexually Transmitted Infections Impacting Women at the 2022 Academy of Managed Care Pharmacy Annual Meeting
Phase 2B/3 AMPREVENCE Clinical Trial Concluded with Women Experiencing a 50 Percent Risk Reduction in Chlamydia Trachomatis (chlamydia) and a 78 Percent Risk Reduction in Neisseria Gonorrhoeae (gonorrhea) using EVO100 (investigational name for Phexxi® (lactic acid, citric acid, and potassium bitartrate)) Compared to PlaceboAMPREVENCE Also Incorporated Direct Patient Health Outcomes Related to Sexual SatisfactionPositive AMPREVENCE Data Serve as the Foundation for the Ongoing, Confirmatory and Registrational Phase 3 EVOGUARD Trial Investigating EVO100 to Prevent Chlamydia and Gonorrhea in Wom
Mar 04, 2022 05:48 am ET
Evofem Completes Enrollment in EVOGUARD Phase 3 Clinical Trial of EVO100 for Prevention of Chlamydia and Gonorrhea in Women
SAN DIEGO, March 4, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) announced today that it has completed enrollment in EVOGUARD, the registrational Phase 3 clinical trial evaluating EVO100 (the investigational name for Phexxi® (lactic acid, citric acid, potassium bitartrate)) for two potential new indications: the prevention of chlamydia infection in women and the prevention of urogenital gonorrhea infection in women.
Mar 03, 2022 03:00 pm ET
Evofem Biosciences Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Corporate Update
SAN DIEGO, March 3, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (Nasdaq: EVFM), a commercial stage biopharmaceutical company, today reported financial results for the three- and twelve-month periods ended December 31, 2021.
Feb 17, 2022 08:00 am ET
Evofem Biosciences to Report Fourth Quarter and Year-End 2021 Results and Provide Corporate Update on Thursday, March 3, 2022
SAN DIEGO, Feb. 17, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the fourth quarter and year ended December 31, 2021 on Thursday, March 3, 2022 at 4:30 p.m. ET (1:30 p.m. PT).
Feb 09, 2022 08:00 am ET
FDA Awards QIDP Designation for Prevention of Chlamydia to Evofem Biosciences
SAN DIEGO, Feb. 9, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) announced today that the U.S. Food and Drug Administration (FDA) has awarded "Qualified Infectious Disease Product" (QIDP) Designation to EVO100 (the investigational name for Phexxi® (lactic acid, citric acid and potassium bitartrate)) for the prevention of urogenital chlamydia infection in women, a potential new indication in late stage clinical development.  Chlamydia is the most frequently reported bacterial infection in the United States. 
Feb 08, 2022 08:00 am ET
Evofem Biosciences to Present at Aegis Virtual Conference on Wednesday, February 23, 2022
SAN DIEGO, Feb. 8, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will present at the Aegis Virtual Conference as follows:
Jan 19, 2022 08:00 am ET
Evofem Biosciences Announces Record Net Sales and Phexxi Prescriptions in Q4 2021
SAN DIEGO, Jan. 19, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced strong preliminary results for the fourth quarter of 2021, including record growth in net product sales of its hormone-free prescription contraceptive gel, Phexxi® (lactic acid, citric acid and potassium bitartrate).
Jan 12, 2022 07:35 am ET
Thinking about buying stock in Jaguar Health, Evofem Biosciences, Adverum Biotechnologies, FREYR Battery, or Planet Labs?
NEW YORK, Jan. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JAGX, EVFM, ADVM, FREY, and PL.
Jan 12, 2022 05:00 am ET
Phexxi Access to Expand under New Government Guidance Stating Insurers Must Cover FDA-approved Contraceptives with No Out-of-Pocket Costs to Women
SAN DIEGO, Jan. 12, 2022 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today commended the Health Resources and Services Administration (HRSA) and the U.S. Department of Labor on their separately-issued updated guidance related to contraceptive access. 
Jan 04, 2022 06:00 am ET
Evofem Biosciences to Present at H.C. Wainwright BioConnect Conference
SAN DIEGO, Jan. 4, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that the Company will present and host one-on-one meetings at the H.C. Wainwright BioConnect Virtual Conference being held from January 10 – 13, 2022.
Dec 16, 2021 06:00 am ET
Evofem Biosciences and Orion Biotechnology Launch Collaboration to Develop MPT Product Candidate to Include HIV Prevention
SAN DIEGO, Dec. 16, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) and Orion Biotechnology Canada Ltd. today announced that they have entered into a collaboration agreement to evaluate the compatibility and stability of Orion's novel CCR5 antagonist, OB-002, in Evofem's Phexxi® (lactic acid, citric acid and potassium bitartrate) vaginal gel with the goal of developing a Multipurpose Prevention Technology (MPT) product candidate for indications including the prevention of HIV in women.
Dec 16, 2021 06:00 am ET
Evofem Biosciences and Orion Biotechnology Launch Collaboration to Develop MPT Product Candidate to Include HIV Prevention
SAN DIEGO, Dec. 16, 2021 /CNW/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) and Orion Biotechnology Canada Ltd. today announced that they have entered into a collaboration agreement to evaluate the compatibility and stability of Orion's novel CCR5 antagonist, OB-002, in Evofem's Phexxi® (lactic acid, citric acid and potassium bitartrate) vaginal gel with the goal of developing a Multipurpose Prevention Technology (MPT) product candidate for indications including the prevention of HIV in women.
Dec 09, 2021 07:00 am ET
Evofem Biosciences Expects Record High Phexxi Prescriptions and Strong Net Revenue Growth in Fourth Quarter 2021
SAN DIEGO, Dec. 9, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced bullish expectations for prescription and net revenue growth in the fourth quarter of 2021.
Dec 08, 2021 05:30 am ET
Evofem Biosciences to Adjourn Special Meeting of Stockholders on December 8, 2021
SAN DIEGO, Dec. 8, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that it intends to adjourn, without conducting any business, its 2021 special meeting of stockholders (the "Special Meeting") scheduled to occur at 8:00 a.m. PST on December 8, 2021, and reconvene at 8:00 a.m. PST on December 15, 2021, to vote on the proposal described in the proxy statement filed with the Securities and Exchange Commission (the "SEC") on November 9, 2021.
Nov 30, 2021 07:00 am ET
Evofem Biosciences Announces Successful Type C Meeting with FDA for STI Prevention Product Candidate
SAN DIEGO, Nov. 30, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today reported a successful Type C meeting with the U.S. Food and Drug Administration in which agreement was reached on the preliminary submission strategy for EVO100 for two investigational indications: the prevention of urogenital chlamydia in women and the prevention of urogenital gonorrhea in women.  There are currently no FDA-approved prescription products to prevent either of these sexually transmitted infections (STIs).
Nov 22, 2021 05:50 am ET
Evofem Biosciences Successfully Extends Cumulative Net Sales Covenant Timing to June 30, 2023
SAN DIEGO, Nov. 22, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that it has successfully extended the cumulative net sales covenant timing of its April 2020 Securities Purchase and Security Agreement to June 30, 2023.
Nov 19, 2021 06:00 am ET
Evofem Biosciences to Participate in Piper Sandler 33rd Annual Healthcare Conference
SAN DIEGO, Nov. 19, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier will participate in a fireside chat and host one-on-one meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held from November 29 – December 2, 2021.
Nov 15, 2021 03:00 pm ET
Evofem Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 15, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), today reported financial results for the three- and nine-month periods ended September 30, 2021.
Nov 10, 2021 06:00 am ET
Evofem Biosciences Announces Regulatory Submission in Mexico for Its Hormone-Free Contraceptive
SAN DIEGO, Nov. 10, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that it has submitted the registration for its hormone-free contraceptive vaginal gel to the Mexican Regulatory Agency COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios).
Nov 04, 2021 08:00 am ET
Evofem Biosciences to Participate in Stifel 2021 Virtual Healthcare Conference
SAN DIEGO, Nov. 4, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier will participate in the Stifel 2021 Virtual Healthcare Conference as follows:
Oct 28, 2021 08:00 am ET
Evofem Biosciences to Report Third Quarter 2021 Results and Provide Corporate Update on Monday, November 15, 2021
SAN DIEGO, Oct. 28, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the third quarter ended September 30, 2021 on Monday, November 15, 2021 at 4:30 p.m. ET (1:30 p.m. PT).
Oct 20, 2021 08:00 am ET
"House Rules" Delivers Strong Initial Results and Drives Phexxi Growth
SAN DIEGO, Oct. 20, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced significant initial results of "House Rules," its national direct-to-consumer (DTC) campaign with celebrity spokeswoman Annie Murphy, aimed at broadening awareness and driving uptake of its hormone-free contraceptive, Phexxi® (lactic acid, citric acid and potassium bitartrate) vaginal gel.
Oct 12, 2021 06:31 am ET
Evofem Biosciences Announces $10 Million Registered Direct Offering of Series B Preferred Stock
SAN DIEGO, Oct. 12, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that it has entered into a definitive agreement with Keystone Capital Partners ("Keystone Capital") providing for the issuance and sale of an aggregate of 10,000 shares of Series B Convertible Stock in a registered direct offering for a purchase price of $1,000.00 per share. The aggregate gross proceeds from this offering are expected to be an aggregate of approximately $10.0 million, before deducting estimated offering expenses payable by Evofem, and will close in two equal tranches with the sec
Oct 08, 2021 08:00 am ET
Evofem Biosciences Commends House of Representatives Leaders for Action to Ensure Coverage for the Full Range of Contraceptives Under ACA
SAN DIEGO, Oct. 8, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today commented on a letter from leaders in the House of Representatives to senior Biden Administration officials calling for action to ensure coverage for the full range of contraceptives under the Affordable Care Act (ACA).
Sep 30, 2021 08:00 am ET
Evofem Biosciences to Present at LD Micro Investor Conference on October 12, 2021
SAN DIEGO, Sept. 30, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier will present and host one-on-one meetings at the 14th annual LD Micro Main Event being held in Los Angeles on October 12-14, 2021.
Sep 27, 2021 08:00 am ET
Evofem Biosciences Announces Publication in Peer-Reviewed Journal Advances in Therapy
SAN DIEGO, Sept. 27, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that a manuscript on the variability of contraceptive clinical trial design and its impact on efficacy outcomes has been published in the peer-reviewed journal Advances in Therapy.
Sep 16, 2021 08:00 am ET
Seven Abstracts to be Presented on Evofem Biosciences' Vaginal pH Modulator
SAN DIEGO, Sept. 16, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that seven data sets from clinical trials of Phexxi® (lactic acid, citric acid and potassium bitartrate) and EVO100 will be presented at four medical society meetings in October 2021.
Sep 09, 2021 08:00 am ET
Emmy® Award Winner Annie Murphy Partners with Evofem Biosciences to Talk Sex, Contraception, and Why She Chose Phexxi®
SAN DIEGO, Sept. 9, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced their partnership with Emmy® Award-winning actress Annie Murphy to launch "House Rules," a national campaign to generate awareness of Evofem's hormone-free contraceptive, Phexxi, while also highlighting the contraceptive journey of millions of women, like Annie, who are tired of dealing with the side effects of hormones in their birth control.
Sep 01, 2021 08:00 am ET
Evofem Biosciences to Participate in Investor Conferences
SAN DIEGO, Sept. 1, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier will present and host one-on-one meetings at two upcoming investor conferences as follows: 
Aug 11, 2021 04:27 pm ET
Evofem Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 11, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), today reported financial results for the three- and six-month periods ended June 30, 2021.
Jul 28, 2021 08:00 am ET
Evofem Biosciences to Report Second Quarter 2021 Results and Provide Corporate Update on Wednesday, August 11, 2021
SAN DIEGO, July 28, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter ended June 30, 2021 on Wednesday, August 11, 2021 at 4:30 p.m. ET (1:30 p.m. PT).
Jul 14, 2021 08:00 am ET
Early Look at Second Quarter Metrics for Phexxi® Reveals Strong Growth
SAN DIEGO, July 14, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today provided a preliminary look at Phexxi® (lactic acid, citric acid and potassium bitartrate) data for the second quarter of 2021 and revealed new insights into the demographics of women who are using this hormone-free contraceptive method.   
Jun 21, 2021 08:30 am ET
Thinking about buying stock in Anavex Life Sciences, Globalstar, Rapt Therapeutics, Aytu Biopharma, or Evofem Biosciences?
NEW YORK, June 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVXL, GSAT, RAPT, AYTU, and EVFM.
Jun 14, 2021 10:50 am ET
Thinking about buying stock in Evofem Biosciences, Clean Energy Fuels, Luokung Technology, Mediaco Holding, or FuelCell Energy?
NEW YORK, June 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EVFM, CLNE, LKCO, MDIA, and FCEL.
Jun 11, 2021 11:00 am ET
Thinking about buying stock in Amesite, ContextLogic, Sundial Growers, Evofem Biosciences, or Curis?
NEW YORK, June 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMST, WISH, SNDL, EVFM, and CRIS.
Jun 08, 2021 11:35 am ET
Thinking about buying stock in Naked Brand, Palantir Technologies, Nokia, Evofem Biosciences, or Micron?
NEW YORK, June 8, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NAKD, PLTR, NOK, EVFM, and MU.
Feb 23, 2021 07:00 am ET
Evofem Biosciences to Present at H.C. Wainwright Global Life Sciences Conference
SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will present at the upcoming H.C. Wainwright Global Life Sciences Conference. Evofem's CEO, Saundra Pelletier, will provide an update on the commercialization of its non-hormonal, use-it-only-when-you-need-it birth control method, Phexxi® (lactic acid, citric acid and potassium bitartrate) vaginal gel.
Feb 18, 2021 07:00 am ET
Evofem Biosciences to Report Fourth Quarter and Year-End 2020 Results and Provide Corporate Update on Thursday, March 4, 2021
SAN DIEGO, Feb. 18, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company's financial results and business highlights for the fourth quarter and year ended December 31, 2020 as follows:
Feb 16, 2021 07:00 am ET
Evofem Biosciences Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of Phexxi®, A Non-Hormonal Birth Control Option for Women
SAN DIEGO, Feb. 16, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced the launch of "Get Phexxi", a national direct-to-consumer (DTC) campaign aimed at broadening awareness of its non-hormonal, use-it-only-when-you-need-it birth control method, Phexxi® (lactic acid, citric acid and potassium bitartrate).
Feb 04, 2021 08:00 am ET
Evofem Biosciences and NCODA Announce Collaboration to Educate Oncology Community about Phexxi®, A Non-Hormonal Birth Control Option for Women with Cancer
SAN DIEGO, Feb. 4, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) and NCODA (National Community Oncology Dispensing Association, Inc.), a premier educational platform for community and academic oncology practices nationwide, are launching a collaboration to positively impact the quality of life for female patients living with, fighting and recovering from cancer by raising awareness about the importance and availability of a new non-hormonal birth control method, Phexxi® (lactic acid, citric acid and potassium bitartrate).
Jan 12, 2021 08:05 am ET
Evofem Biosciences Wins Business Intelligence Group's BIG Innovation Award 2021
SAN DIEGO, Jan. 12, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) has been named a winner of Business Intelligence Group's 2021 BIG Innovation Awards for outstanding innovation with first-in-class non-hormonal prescription contraceptive vaginal gel, Phexxi® (lactic acid, citric acid and potassium bitartrate). This annual business awards program recognizes organizations, products, and people that are bringing new ideas to life in innovative ways.
Dec 22, 2020 06:00 am ET
Evofem Biosciences to Participate in Medicaid National Drug Rebate Program for Phexxi® Effective January 1, 2021
SAN DIEGO, Dec. 22, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it has entered into an agreement with the U.S. Centers for Medicare and Medicaid Services (CMS) to participate in the Medicaid National Drug Rebate Program (NDRP), providing access to Phexxi® (lactic acid, citric acid and potassium bitartrate) for the Medicaid population effective January 1, 2021.
Dec 21, 2020 08:00 am ET
Evofem Biosciences to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
SAN DIEGO, Dec. 21, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference.
Dec 17, 2020 06:00 am ET
Evofem Biosciences Provides Update on Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea
SAN DIEGO, Dec. 17, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that its pivotal Phase 3 trial, 'EVOGUARD,' of EVO100 for the prevention of chlamydia and gonorrhea remains firmly on schedule. EVOGUARD was initiated and the first patient was enrolled in October 2020, and study enrollment targets were met in both October and November 2020 despite the ongoing COVID-19 pandemic.
Dec 11, 2020 07:00 am ET
Evofem Biosciences Announces Orange Book Listing of Two U.S. Patents for Phexxi®
SAN DIEGO, Dec. 11, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that two U.S. patents which cover Phexxi® (lactic acid, citric acid and potassium bitartrate) and its labeled indication are now listed in the U.S. Food and Drug Administration (FDA) publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.
Dec 03, 2020 06:00 am ET
The U.S. Department of Veterans Affairs Awards Contract to Evofem Biosciences for Phexxi®
SAN DIEGO, Dec. 3, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that the U.S. Department of Veterans Affairs (VA) has awarded the Company a contract for the purchase of Phexxi® (lactic acid, citric acid and potassium bitartrate) for a five-year period beginning December 15, 2020.
Nov 20, 2020 07:30 am ET
Evofem Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
SAN DIEGO, Nov. 20, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference, taking place virtually November 30 through December 3, 2020.
Nov 12, 2020 07:30 am ET
Evofem Biosciences to Present at Stifel Virtual Healthcare Conference
SAN DIEGO, Nov. 12, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will present at the Stifel Virtual Healthcare Conference on Wednesday November 18, 2020 at 4:00 p.m. ET.
Nov 09, 2020 03:01 pm ET
Evofem Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), today reported financial results for the three- and nine- month periods ended September 30, 2020.
Oct 27, 2020 08:00 am ET
Evofem Biosciences to Report Third Quarter 2020 Results and Provide Corporate Update on Monday, November 9, 2020
SAN DIEGO, Oct. 27, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company's financial results and business highlights for the third quarter ended September 30, 2020 as follows:
Oct 26, 2020 09:00 am ET
Evofem Biosciences to Participate in Virtual Investor KOL Roundtable
SAN DIEGO, Oct. 26, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) announced today that members of management will participate in a Virtual Investor KOL Roundtable on Thursday, October 29, 2020 at 2:00 p.m. ET.
Oct 20, 2020 08:00 am ET
Evofem Biosciences Announces First Patient Enrolled in Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea
SAN DIEGO, Oct. 20, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced enrollment of the first patient in its pivotal Phase 3 clinical trial evaluating the safety and efficacy of EVO100 for the prevention of urogenital chlamydia and gonorrhea in women.  
Oct 15, 2020 08:00 am ET
Evofem Biosciences Secures $25 Million Strategic Investment from Adjuvant Capital
SAN DIEGO, Oct. 15, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) announced today that it has sold $25 million of unsecured convertible promissory notes to funds affiliated with Adjuvant Capital, LP ("Adjuvant Capital"). The notes are convertible into shares of Evofem common stock at a conversion price of $3.65 per share. Proceeds from the sale of the notes will be used to support EVOGUARD, Evofem's planned Phase 3 clinical trial of EVO100 for the prevention of urogenital chlamydia and gonorrhea in women, and to expand global market access for Phexxi™ (lactic acid, citric aci
Aug 04, 2020 08:00 am ET
Evofem Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 4, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a commercial stage biopharmaceutical company, today reported financial results for the three- and six- month periods ended June 30, 2020.
Aug 03, 2020 08:30 am ET
Evofem Biosciences' CEO Saundra Pelletier Named to PharmaVOICE100 - The Most Inspiring People in Life Sciences
SAN DIEGO, Aug. 3, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) is proud to announce that CEO Saundra Pelletier was named to the PharmaVOICE 100 Most Inspiring People, an annual list of the 100 most innovative, influential and inspirational people in the life-sciences industry.
Jul 23, 2020 08:30 am ET
Evofem Biosciences to Report Second Quarter 2020 Results and Provide Corporate Update on Tuesday, August 4, 2020
SAN DIEGO, July 23, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company's financial results and business highlights for the second quarter ended June 30, 2020.
Jul 15, 2020 08:30 am ET
Evofem Biosciences Announces Peer-Reviewed Publication of the Pivotal Phase 3 AMPOWER Study Results For Phexxi™ (lactic acid, citric acid and potassium bitartrate) in Contraception
SAN DIEGO, July 15, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a commercial-stage biopharmaceutical company, today announced that Contraception, an international, peer-reviewed, reproductive health journal, published the primary efficacy and safety results from the Phase 3 AMPOWER study evaluating Phexxi™  (lactic acid, citric acid and potassium bitartrate) for the prevention of pregnancy. The results were published "online first" this week in Contraception: X (https://bit.ly/38HLFBh) and will appear in a future print edition of the journal.
Jul 01, 2020 08:01 am ET
Evofem Biosciences Issues Mid-Year 2020 Letter to Stockholders
SAN DIEGO, July 1, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a commercial-stage biopharmaceutical company, today announced that it has issued a letter to its stockholders providing an update on recent events and outlook for the remainder of 2020 and early 2021.
Jun 03, 2020 10:55 am ET
Thinking about buying stock in Zomedica Pharmaceuticals, InspireMD, General Electric, Norwegian Cruise Line, or Evofem Biosciences?
NEW YORK, June 3, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZOM, NSPR, GE, NCLH, and EVFM.
Jun 02, 2020 11:03 pm ET
Evofem Announces Pricing of Approximately $100 Million Public Offering of Common Stock
SAN DIEGO, June 2, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, today announced the pricing of an underwritten public offering of 28,500,000 shares of its common stock at a price to the public of $3.50 per share. The gross proceeds from the offering to Evofem, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $100 million. The offer
Jun 02, 2020 04:01 pm ET
Evofem Announces Proposed Public Offering of Common Stock
SAN DIEGO, June 2, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, Evofem expects to grant the underwriters a 30-day option to purchase up to an additional 15% of shares of its common stock offered in the offering at the public offering
May 26, 2020 09:31 am ET
Thinking about buying stock in Evofem Biosciences, Village Farms, Atara Biotherapeutics, Cronos Group, or American Airlines?
NEW YORK, May 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EVFM, VFF, ATRA, CRON, and AAL.
May 22, 2020 04:05 pm ET
U.S. FDA Approves Evofem Biosciences' Phexxi™ (lactic acid, citric acid and potassium bitartrate), the First and Only Non-Hormonal Prescription Gel for the Prevention of Pregnancy
SAN DIEGO, May 22, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that the U.S. Food and Drug Administration (FDA) has approved Phexxi™ (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.
May 21, 2020 04:05 pm ET
PDL BioPharma Completes Distribution of Evofem Biosciences Common Stock to PDL Stockholders
INCLINE VILLAGE, Nev., May 21, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces that it has completed its previously announced distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc. ("Evofem") (Nasdaq: EVFM), which represented approximately 26.7% of the outstanding shares of Evofem common stock as of the close of business on May 15, 2020 (the "record date").
May 18, 2020 04:05 pm ET
PDL BioPharma Declares Distribution Ratio for Dividend of Evofem Biosciences Common Stock to PDL Stockholders
INCLINE VILLAGE, Nev., May 18, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the final distribution ratio for the previously announced distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc. ("Evofem") (Nasdaq: EVFM) to be made on May 21, 2020 (the "distribution date").  Based on the shares of PDL common stock outstanding as of the close of business on May 15, 2020 (the "record date"), PDL stockholders of record as of the record date will be entitled to receive 0.11591985 shares of Evofem common stock
May 13, 2020 08:00 am ET
Evofem Biosciences to Participate in Virtual Fireside Chat at RBC Capital Markets Global Healthcare Conference
SAN DIEGO, May 13, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today announced that it will participate in the upcoming 2020 RBC Capital Markets Global Healthcare Conference.
May 06, 2020 08:00 am ET
Evofem Biosciences Reports First Quarter 2020 Financial Results and Provides Corporate Update
SAN DIEGO, May 6, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today reported financial results for the three-month period ended March 31, 2020.
May 05, 2020 04:05 pm ET
PDL BioPharma Declares Dividend of Evofem Biosciences Common Stock to PDL Stockholders
INCLINE VILLAGE, Nev., May 5, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that the Company's Board of Directors has approved a distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc. ("Evofem") (Nasdaq: EVFM) via a special one-time dividend to PDL stockholders.
May 01, 2020 05:21 pm ET
Evofem Biosciences Announces New Location and COVID-19 Preventative Measures for 2020 Annual Meeting Scheduled for May 12, 2020
SAN DIEGO, May 1, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today announced that the location of its annual general meeting scheduled for May 12, 2020 at 8:00 am PDT has been moved to the 6th floor boardroom at 12400 High Bluff Dr., San Diego, CA 92130.
Apr 28, 2020 08:00 am ET
Evofem Biosciences to Report First Quarter 2020 Results and Provide Corporate Update on Wednesday, May 6, 2020
SAN DIEGO, April 28, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today announced that it will host a webcast and conference call to discuss the Company's financial results for the first quarter ended March 31, 2020, and provide a general business overview, on Wednesday, May 6, 2020 at 11:00 a.m. ET (8:00 a.m. PT).
Apr 27, 2020 08:00 am ET
Evofem Biosciences Secures up to $25 Million in Convertible Note Financing
SAN DIEGO, April 27, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today announced that it has entered into a private Securities Purchase Agreement with a U.S.-based, healthcare-focused institutional investor (the "Investor") for up to $25 million of convertible notes.
Apr 24, 2020 08:30 am ET
Evofem Biosciences Announces Three New Phexxi™ Data Sets Accepted for Presentation at the 2020 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting
SAN DIEGO, April 24, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today announced that three new data sets from the Company's Phase 3 AMPOWER trial evaluating Phexxi™, a first-in-class investigational Multipurpose Vaginal pH Regulator (MVP-R™) for the prevention of pregnancy, were accepted for poster presentations at the 2020 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting and published in the esteemed journal, Obstetrics & Gynecology (The Green Journal).
Apr 10, 2020 04:05 pm ET
Evofem Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 10, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today announced that on April 9, 2020, the Compensation Committee of the Company's Board of Directors approved the grant to 20 new employees of (i) non-qualified stock option awards to purchase an aggregate of 357,000 shares of common stock, and (ii) 20,000 restricted shares of common stock awards in aggregate.
Mar 27, 2020 08:30 am ET
Evofem Biosciences to Present at Solebury Trout Virtual Investor Conference
SAN DIEGO, March 27, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, announced today that Chief Executive Officer Saundra Pelletier will present an overview of the Company and business updates at the upcoming Solebury Trout Virtual Investor Conference.
Mar 25, 2020 05:00 pm ET
Evofem Biosciences Adopts Shareholder Rights Agreement
SAN DIEGO, March 25, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, today announced that its Board of Directors has adopted a shareholder rights agreement (the "Rights Agreement"), effective March 24, 2020, under which its stockholders will receive a dividend in the form of preferred stock purchase rights (the "Rights"). The record date for the dividend has been fixed as April 8, 2020.
Mar 24, 2020 04:00 pm ET
Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies
NEW YORK, NY / ACCESSWIRE / March 24, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a Virtual Conference Series on March 26, March 31, and April 2, 2020, featuring leading companies from the life sciences industry. At the event, management teams will present a business overview and highlights using an online, digital meeting format.
Mar 19, 2020 08:15 am ET
TRACON Pharmaceuticals Announces Appointment of Saundra Pelletier to Board of Directors
TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S....
Nov 14, 2019 07:00 am ET
Evofem Biosciences' CEO Saundra Pelletier Awarded 2019 Business Woman Of The Year
SAN DIEGO, Nov. 14, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier was named a 2019 Business Woman of the Year by the San Diego Business Journal. The publication's annual awards program, hosted Wednesday, November 13, recognized 15 dynamic women business leaders who have contributed significantly to San Diego's workplaces and communities.
Nov 13, 2019 03:05 pm ET
Evofem Biosciences to Participate in Upcoming Investor Conferences
SAN DIEGO, Nov. 13, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, announced today that Chief Executive Officer Saundra Pelletier will present at two upcoming healthcare equity conferences:
Nov 06, 2019 03:05 pm ET
Evofem Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 6, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) a clinical-stage biopharmaceutical company, today reported financial results for the three- and nine-month periods ended September 30, 2019. Third quarter and recent highlights:
Oct 24, 2019 09:00 am ET
Evofem Biosciences to Report Third Quarter 2019 Results and Provide Corporate Update on November 7, 2019
SAN DIEGO, Oct. 24, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company's financial results and business highlights for the third quarter ended September 30, 2019.
Sep 25, 2019 09:00 am ET
Evofem Biosciences to Present at Cantor Global Healthcare Conference on October 4, 2019
SAN DIEGO, Sept. 25, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, will present and host investor meetings at the upcoming 2019 Cantor Global Healthcare Conference in New York, NY.
Aug 26, 2019 06:00 am ET
Evofem Biosciences Completes Phase 2b 'AMPREVENCE' Trial of Amphora for Prevention of Chlamydia and Gonorrhea in Women
SAN DIEGO, Aug. 26, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company") today announced the last patient has completed her last visit in AMPREVENCE, the Phase 2b clinical trial evaluating the Company's lead product candidate Amphora®, a Multipurpose Vaginal pH Regulator (MVP-R™), for the prevention of acquisition of chlamydia and gonorrhea in women (as primary and secondary endpoints, respectively).
Aug 22, 2019 09:30 am ET
Evofem Biosciences to Present at Upcoming Healthcare Conferences
SAN DIEGO, Aug. 22, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, is set to present at two healthcare equity conferences in early September.
Aug 05, 2019 04:10 pm ET
Evofem Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 5, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical stage biopharmaceutical company, today reported financial results for the three- and six- month period ended June 30, 2019. Second quarter and recent highlights include:
Aug 05, 2019 04:05 pm ET
Evofem Biosciences Reports Additional Data from Phase 3 'AMPOWER' Study of Amphora® for Hormone-Free Birth Control
SAN DIEGO, Aug. 5, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) (Evofem), a clinical-stage biopharmaceutical company, today reported additional data from its Phase 3 'AMPOWER' clinical trial of Amphora® for the prevention of pregnancy.  These findings reveal that the use of Amphora, a first-in-class investigational Multipurpose Vaginal pH Regulator (MVP-R™), may improve sexual satisfaction and have a positive impact on women's sex lives.  The analysis also confirmed certain previously reported safety and efficacy data.
Jul 30, 2019 09:00 am ET
Evofem Biosciences to Report Second Quarter 2019 Results and Provide Corporate Update on August 6, 2019
SAN DIEGO, July 30, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a conference call to discuss financial results and business highlights for the second quarter ended June 30, 2019, as follows:
Jul 01, 2019 09:31 am ET
Evofem Biosciences Added to Russell 3000® Index
SAN DIEGO, July 1, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) (Evofem), a clinical-stage biopharmaceutical company was added to the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective at the U.S. market open on July 1, 2019, according to a final list of additions posted June 28.
May 14, 2019 09:00 am ET
Evofem Biosciences to Present at 2019 RBC Capital Markets Global Healthcare Conference
SAN DIEGO, May 14, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, announced today that its Chief Executive Officer, Saundra Pelletier, will present at the 2019 RBC Capital Markets Global Healthcare Conference on Wednesday, May 22, 2019 at 10:30 AM EDT.  The conference will be held at the InterContinental New York Barclay Hotel in New York, NY.
May 07, 2019 06:00 am ET
Evofem Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update
SAN DIEGO, May 7, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical stage biopharmaceutical company, today reported financial results for the three- month period ended March 31, 2019. First quarter and recent highlights include:
Apr 30, 2019 09:00 am ET
Evofem Biosciences to Report First Quarter 2019 Results and Provide Corporate Update on May 7, 2019
SAN DIEGO, April 30, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a conference call to discuss financial results and business highlights for the first quarter ended March 31, 2019, as follows:
Apr 23, 2019 08:11 am ET
Evofem Biosciences Announces Last Patient Enrolled for AMPREVENCE, the Phase 2b Sexually Transmitted Infections Trial of Amphora
SAN DIEGO, April 23, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) ("Evofem"), a clinical stage biopharmaceutical company, today announced the completion of patient enrollment in AMPREVENCE, the Phase 2b clinical trial evaluating its lead product candidate Amphora®, a Multipurpose Vaginal pH Regulator™ (MVP-R), for the prevention of chlamydia and gonorrhea in women.
Apr 16, 2019 08:30 am ET
STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Evofem Biosciences, Inc. – EVFM
Kaskela Law LLC is investigating Evofem Biosciences, Inc. (“Evofem” or the “Company”) (NASDAQ: EVFM) on behalf of the Company’s stockholders.  The investigation seeks to determine whether members of Evofem’s board of directors breached their...
Apr 11, 2019 10:25 am ET
PDL BioPharma Announces Equity Investment in Evofem Biosciences
INCLINE VILLAGE, Nev., April 11, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that it has entered into a securities purchase agreement with Evofem Biosciences, Inc. ("Evofem") (NASDAQ: EVFM), pursuant to which it will invest a total of up to $60 million in a private placement of securities.  The transaction is expected to have two tranches.  The first tranche comprises $30 million, which was provided today.  In addition, PDL has the right to invest an additional $30 million in a second tranche alongside two existing Evofem shareholders, which hav
Apr 11, 2019 10:19 am ET
Evofem Biosciences Enters into Financing Agreement for up to $80 Million, Closes First Tranche of Strategic Investment from PDL BioPharma
SAN DIEGO, April 11, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) ("Evofem"), today announced it has entered into a securities purchase agreement pursuant to which Evofem can raise up to $80 million through a private placement of common stock from new and existing investors, including a strategic investment from PDL BioPharma, Inc. (NASDAQ: PDLI) ("PDL").  
Apr 03, 2019 09:00 am ET
Evofem Biosciences to Present at Needham Healthcare Conference
SAN DIEGO, Calif., April 3, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM), a clinical-stage biopharmaceutical company, announced today it will present at the 18th Annual Needham Healthcare Conference in New York City as follows:
Mar 12, 2019 09:00 am ET
Evofem Biosciences to Present at Upcoming Investor Conferences
SAN DIEGO, March 12, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company, announced today it will present at the following investor conferences on Tuesday March 19, 2019:
Mar 01, 2019 05:00 am ET
Evofem Biosciences Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
SAN DIEGO, March 1, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical stage biopharmaceutical company, today reported financial results for the three- and twelve- month periods ended December 31, 2018. Fourth quarter and recent highlights include:
Feb 19, 2019 08:00 am ET
Evofem Biosciences to Report Fourth Quarter and Year-end 2018 Results and Provide Corporate Update on March 1, 2019
SAN DIEGO, Feb. 19, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a conference call to discuss financial results and business highlights for the fourth quarter and year ended December 31, 2018, as follows:
Jan 03, 2019 07:00 am ET
Evofem Biosciences Provides Corporate Update and Announces Upcoming Milestones
SAN DIEGO, Jan. 3, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today provided insight into anticipated 2019 milestones and events across its clinical pipeline. The Company recently reported that its Phase 3 trial evaluating Amphora® for the prevention of pregnancy met its primary endpoint, and plans to resubmit the Amphora NDA in the second quarter of 2019. Additional highlights are below.  
Dec 17, 2018 05:00 am ET
Evofem Biosciences Announces Positive Top-Line Results of Phase 3 Study Evaluating Amphora for Hormone-Free Birth Control
SAN DIEGO, Dec. 17, 2018 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) ("Evofem" or the "Company") today announced that its Phase 3 clinical trial of Amphora® for the prevention of pregnancy, AMPOWER, successfully met its primary endpoint.
Nov 15, 2018 05:50 am ET
Evofem Biosciences to Present at Piper Jaffray Healthcare Conference on November 27, 2018
SAN DIEGO, Nov. 15, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company") announced today that the Company will present at the 30th Annual Piper Jaffray Healthcare Conference, as follows:
Nov 08, 2018 05:50 am ET
Evofem Biosciences Completes Phase 3 Clinical Trial of Amphora for Prevention of Pregnancy
SAN DIEGO, Nov. 8, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company") today announced the last patient has completed her last visit in AMPOWER, the second Phase 3 clinical trial of Amphora® (L-lactic acid, citric acid and potassium bitartrate), its lead Multipurpose Vaginal pH Regulator (MVP-R) product candidate, for the prevention of pregnancy.  
Nov 07, 2018 05:50 am ET
Evofem Biosciences Reports Third Quarter 2018 Financial Results and Provides Corporate Update
SAN DIEGO, Nov. 7, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), today reported financial results for the three- and nine- month periods ended September 30, 2018. Recent highlights include:
Nov 01, 2018 08:00 am ET
Evofem Biosciences to Host Key Opinion Leader Event: New Perspectives in Birth Control--Non-Hormonal, On Demand and Woman Controlled
SAN DIEGO, Nov. 1, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, today announced it will host a key opinion leader event in New York City on Thursday, November 15, 2018 from 11:30am to 1:00pm ET: "New Perspectives in Birth Control -- Non-Hormonal, On Demand and Woman Controlled."
Oct 24, 2018 08:30 am ET
Evofem Biosciences to Report Third Quarter 2018 Results on November 7, 2018
SAN DIEGO, Oct. 24, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, will hold a conference call to discuss financial results and business highlights for the quarter ended September 30, 2018, as follows:
Oct 09, 2018 02:21 pm ET
Data on Patient Acceptability and Genitourinary Effects of Evofem Biosciences' Lead Product Candidate, Amphora, and its Role as a Multipurpose Vaginal pH Regulator Presented at 2018 American Society o
SAN DIEGO, Oct. 9, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, announced details of two oral presentations of data related to their lead product, Amphora®, a Multipurpose Vaginal pH Regulator (MVP-R) in late-stage development for prevention of pregnancy and prevention of urogenital transmission of chlamydia in women, at the 2018 American Society for Reproductive Medicine (ASR
Oct 03, 2018 08:00 am ET
Evofem Biosciences to Present Data on Methodology and Current Status of Two Ongoing Clinical Studies of Amphora at the 2018 International Federation of Gynecology and Obstetrics (FIGO) World Congress
SAN DIEGO, Oct. 3, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, will present an update on the methodology and status of two ongoing late stage clinical trials of its lead product candidate, Amphora®. This first-in-class Multipurpose Vaginal pH Regulator (MVP-R) is being studied for prevention of both pregnancy and certain sexually transmitted infections (STIs).
Sep 26, 2018 08:00 am ET
Survey Reveals High Number of Sexually Active Women Who Use No Birth Control Method, Supporting the Continued Need for Non-Hormonal Birth Control Innovations such as Evofem Biosciences' Product Candid
SAN DIEGO, Sept. 26, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, today announced detailed results of its commissioned Consumer Survey conducted by The Harris Poll, which aligns with previously published data by the Guttmacher Institute1-3 and supports the following statistics:
Sep 21, 2018 08:00 am ET
New Data on Patient Acceptability and Genitourinary Effects of Evofem Biosciences' Amphora and its Role as a Multipurpose Vaginal pH Regulator (MVP-R) to be Presented at the 2018 American Society For
SAN DIEGO, Sept. 21, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, announced today that new data from two clinical trials of Amphora®, its lead Multipurpose Vaginal pH Regulator (MVP-R) product candidate, will be presented at the 2018 American Society for Reproductive Medicine (ASRM) Annual Congress taking place in Denver, Colorado on October 9, 2018.
Sep 18, 2018 08:00 am ET
Evofem Biosciences to Present at Upcoming Investor Conferences
SAN DIEGO, Sept. 18, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, announced today that the Company will present at the Cantor Fitzgerald 20th Annual Global Investment Conference as follows:
Aug 29, 2018 09:00 am ET
Rise in Prevalence of STDs Reported by CDC Supports Continued Development of Novel Solutions, Like Evofem's Product in Development, Amphora®, for the Prevention of Chlamydia
SAN DIEGO, Aug. 29, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, believes that new data recently released by the Centers for Disease Control and Prevention (CDC) on the increasing rates of sexually transmitted diseases (STDs) in the United States support the continued need for and clinical development of Amphora® (L-lactic acid, citric acid, and potassium bitartrate) vaginal g
Aug 23, 2018 09:00 am ET
Evofem Biosciences to Present at 20th Annual Global Investment Conference on September 6, 2018
SAN DIEGO, Aug. 23, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, announced today that the Company will present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, as follows:
Aug 07, 2018 09:00 am ET
Evofem Biosciences' Chief Medical Officer, Dr. Kelly Culwell, to Present at #BlogHer18 Creators Summit
SAN DIEGO, Aug. 7, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem"), announced today that its Chief Medical Officer, Kelly Culwell, MD, will present at the #BlogHer18 Creators Summit, presented by SheKnows Media, on Wednesday, August 8, 2018 at 4:05 p.m. EDT in New York City.
Aug 02, 2018 06:50 am ET
Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 2, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, today reported financial results for the three- and six- month periods ended June 30, 2018.
Jul 19, 2018 08:30 am ET
Evofem Biosciences to Report Second Quarter 2018 Results and Provide Corporate Update on August 2, 2018
SAN DIEGO, July 19, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, will hold a conference call to discuss financial results and business highlights for the quarter ended June 30, 2018, as follows:
May 29, 2018 12:00 pm ET
Evofem Biosciences to Present at Jefferies Global Healthcare Conference on June 7, 2018
SAN DIEGO, May 29, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, announced today that Saundra Pelletier, CEO, will present at the Jefferies 2018 Global Healthcare Conference on Thursday, June 7, 2018 at 3:30 p.m. EDT in New York City.
May 24, 2018 04:01 pm ET
Evofem Biosciences Announces Closing of Public Offering of Common Stock and Warrants
SAN DIEGO, May 24, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, today announced the closing of its previously announced underwritten public offering of 8.5 million shares of common stock or, in lieu of shares of common stock, pre-funded warrants exercisable for shares of common stock, and accompanying common warrants to purchase an aggregate of 1.7 million shares of common sto
May 22, 2018 09:00 am ET
Evofem Biosciences Announces Pricing of Public Offering of Common Stock and Warrants
SAN DIEGO, May 22, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, announced today the pricing of an underwritten public offering of up to 8.5 million shares in aggregate of common stock or, in lieu of shares of common stock, pre-funded warrants exercisable for shares of common stock, and accompanying common warrants to purchase an aggregate of 1.7 million shares of common stock.
Apr 24, 2018 06:50 am ET
Evofem Biosciences Announces Proposed Public Offering of Common Stock
SAN DIEGO, April 24, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, announced today the launch of an underwritten public offering of $40.0 million of its common stock. All of the shares in the offering are to be sold by Evofem. As part of the offering, Evofem expects to grant the underwriters a 30-day option to purchase up to an additional $6.0 million of its common stock offere
Feb 21, 2018 05:55 am ET
Evofem Biosciences Receives Fast Track Designation for Amphora for Prevention of Chlamydia
SAN DIEGO, Feb. 21, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a biotechnology company developing innovative products to fill women's unmet healthcare needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Amphora® (L-lactic acid, citric acid, and potassium bitartrate) vaginal gel for the prevention of urogenital chlamydia in women.
Feb 16, 2018 05:55 am ET
Evofem Biosciences to Present at RBC Global Healthcare Conference
SAN DIEGO, Feb. 16, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a biotechnology company developing innovative products to fill women's unmet healthcare needs, today announced that Saundra Pelletier, CEO, will present at the 2018 RBC Capital Markets Global Healthcare Conference as follows:
Feb 15, 2018 05:55 am ET
Evofem Biosciences Completes Enrollment of Phase 3 Contraceptive Trial of Amphora Ahead of Schedule
SAN DIEGO, Feb. 15, 2018 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a biotechnology company developing innovative products to fill women's unmet healthcare needs, announced early completion of enrollment in its Phase 3 clinical trial evaluating Amphora® (L-lactic acid, citric acid, and potassium bitartrate) vaginal gel for the prevention of pregnancy. Trial data is expected in the first quarter of 2019.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.